Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03409211 · ClinicalTrials.gov registry record · NA
Patterns After Administration of MCFAs in Psoriasis and Psoriatic Arthritis
A NA study, sponsored by NYU Langone Health.
- Completed
- Registry status
- NA
- Development phase
- 22
- Enrollment target
NCT03409211 is a NA study that has completed, run by NYU Langone Health. The registered enrollment target is 22 participants.
The verdict
NCT03409211, a NA study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 22 participants
- Enrollment target
Study Summary
This is a proof-of-principle, placebo-controlled, open label study to assess the improvement in the Treg counts and PASI Scores with PEVCO given at 1000 mg four times daily in patients with PsO (subjects may or may not have PsA) , who have active disease and are not currently receiving other therapy (as defined by the inclusion/exclusion criteria) compared to healthy subjects. The patients and healthy controls will receive placebo or PEVCO for a total of 9 weeks (3 weeks for placebo, followed by 6 weeks for PEVCO). No topical or systemic medications will be used during this period.
Interventions
- DIETARY_SUPPLEMENT PEVCO
- DIETARY_SUPPLEMENT Dietary Supplement Capsules without Coconut Oil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2017-12-12 |
| Est. Completion | 2019-09-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03409211
The ClinicalTrials.gov registry entry for NCT03409211 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which PEVCO is the first listed.
NCT03409211 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03409211 about?
NCT03409211 is a clinical study titled "Patterns After Administration of MCFAs in Psoriasis and Psoriatic Arthritis". This is a proof-of-principle, placebo-controlled, open label study to assess the improvement in the Treg counts and PASI Scores with PEVCO given at 1000 mg four times daily in patients with PsO (subjects may or may not have PsA) , who have active disease and are not currently receiving other therapy...
What is the current status of trial NCT03409211?
This trial is currently completed. It is a NA study. The enrollment target is 22 participants. The study started on 2017-12-12. Estimated completion is 2019-09-30.
What interventions are being tested in trial NCT03409211?
The interventions under investigation include: PEVCO (DIETARY_SUPPLEMENT), Dietary Supplement Capsules without Coconut Oil (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT03409211?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.